share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Greene John

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Greene John

CRISPR Therapeutics | 4：持股變動聲明-董事 Greene John
美股sec公告 ·  06/01 04:21
牛牛AI助理已提取核心訊息
In a recent transaction, John Greene, associated with CRISPR Therapeutics (CRSP.US), executed a stock action on 05/30/2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and post-action shareholding, were not disclosed in the announcement. Investors are advised to monitor CRISPR Therapeutics for any further disclosures that may provide additional insights into the transaction's impact on the company's stock.
In a recent transaction, John Greene, associated with CRISPR Therapeutics (CRSP.US), executed a stock action on 05/30/2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and post-action shareholding, were not disclosed in the announcement. Investors are advised to monitor CRISPR Therapeutics for any further disclosures that may provide additional insights into the transaction's impact on the company's stock.
在最近的一筆交易中，與CRISPR Therapeutics（CRSP.US）相關的約翰·格林於2024年5月30日執行了股票行動。公告中未披露該交易的具體細節，包括行動類型、狀態、所涉股份數量、股票性質、交易價格和事後持股。建議投資者關注CRISPR Therapeutics是否有任何進一步的披露，這些披露可能爲該交易對公司股票的影響提供更多見解。
在最近的一筆交易中，與CRISPR Therapeutics（CRSP.US）相關的約翰·格林於2024年5月30日執行了股票行動。公告中未披露該交易的具體細節，包括行動類型、狀態、所涉股份數量、股票性質、交易價格和事後持股。建議投資者關注CRISPR Therapeutics是否有任何進一步的披露，這些披露可能爲該交易對公司股票的影響提供更多見解。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。